Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023
Anticipates Topline Data from Phase 3 REACH Trial in Q4 2024; Strengthens Cash Position
Source: yahoo.com
Stay updated with breaking news from Flow Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Anticipates Topline Data from Phase 3 REACH Trial in Q4 2024; Strengthens Cash Position
Non-Respiratory Segment Shows Strength While Respiratory Demand Weakens
Investegate announcements from Final Results
Challenges in International Markets Lead to Earnings Dip
Strong Financial Results Revenue at $307 million, up 42% y-o-y EBITDAs at $109 million, up 41% y-o-y Positive Net Cash Flow of $63 million PARIS, France – November 6, 2023 – CGG ,...